Condition: Adenocarcinoma · Carcinoma, Pancreatic Ductal · Sponsor: Corcept Therapeutics
This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).
This description comes directly from the study's public registry record.
Corcept Therapeutics · (650) 815-1595 · corceptstudy558@corcept.com
Always discuss trial participation with your own doctor first.
| Site 02 | Scottsdale, Arizona, United States | Recruiting |
| Site 04 | Los Angeles, California, United States | Recruiting |
| Site 12 | Orange, California, United States | Recruiting |
| Site 06 | Atlanta, Georgia, United States | Recruiting |
| Site 14 | Goshen, Indiana, United States | Recruiting |
| Site 15 | Westwood, Kansas, United States | Recruiting |
| Site 03 | Grand Rapids, Michigan, United States | Recruiting |
| Site 10 | East Brunswick, New Jersey, United States | Recruiting |
| Site 11 | Morristown, New Jersey, United States | Recruiting |
| Site 08 | Albany, New York, United States | Recruiting |
| Site 05 | Lake Success, New York, United States | Withdrawn |
| Site 07 | Shirley, New York, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07259317